| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,148 |
7,822 |
$702K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
5,217 |
2,742 |
$331K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,526 |
2,954 |
$265K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,588 |
2,053 |
$263K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,097 |
3,603 |
$232K |
| 99215 |
Prolong outpt/office vis |
2,281 |
1,890 |
$219K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
7,949 |
5,961 |
$211K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,748 |
2,597 |
$119K |
| 87631 |
|
946 |
866 |
$111K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,979 |
2,455 |
$103K |
| 96127 |
|
1,938 |
1,400 |
$24K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
293 |
257 |
$15K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
329 |
294 |
$11K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,173 |
1,241 |
$11K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
88 |
78 |
$11K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,561 |
1,014 |
$10K |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
505 |
318 |
$9K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
178 |
160 |
$8K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
470 |
450 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
525 |
456 |
$7K |
| 87634 |
|
77 |
61 |
$4K |
| 99000 |
|
4,658 |
2,373 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
344 |
306 |
$4K |
| 81002 |
|
1,928 |
1,350 |
$4K |
| 71046 |
Radiologic examination, chest; 2 views |
111 |
68 |
$2K |
| 81025 |
|
229 |
161 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
50 |
26 |
$445.11 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
436 |
381 |
$265.29 |
| 90686 |
|
13 |
13 |
$197.67 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
912 |
787 |
$87.63 |
| 36415 |
Collection of venous blood by venipuncture |
20 |
16 |
$42.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
263 |
217 |
$8.63 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
43 |
42 |
$6.11 |